Biocon Ltd. (BION)

Currency in INR
368.50
+1.25(+0.34%)
Closed·
Advertisement
BIOCON is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
365.00375.45
52 wk Range
318.40447.15
Key Statistics
Bid/Ask
368.00 / 368.50
Prev. Close
368.5
Open
365.25
Day's Range
365-375.45
52 wk Range
318.4-447.15
Volume
2.96M
Average Volume (3m)
3.07M
1-Year Change
-3.5719%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BIOCON Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
415.00
Upside
+12.62%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

Biocon Ltd. News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

12 Buy
2 Hold
4 Sell
Ratings:
18 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 415.00
(+12.62% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
ICICI Securities
Sell330.00-10.45%350.00Maintain09/11/2026
HSBC
Buy440.00+19.40%460.00Maintain05/11/2026
Kotak
Buy390.00+5.83%-Upgrade05/11/2026
Axis Capital Limited
Buy395.00+7.19%405.00Upgrade30/10/2026
BofA Securities
Sell410.00+11.26%-Downgrade10/08/2026

Biocon Ltd. Earnings Call Summary for Q2/2027

  • Biocon posted 6% H1 FY2027 revenue growth to INR 8,725 crore with 20% EBITDA margin; Q2 revenue rose just 2% year-over-year to INR 865 crore.
  • One-time logistics delay deferred ~5% of Q2 biosimilar revenue (INR 135-138 crore) into October; management expects stronger H2 performance.
  • YESINTEK holds 34% U.S. market share; YESAFILI has 50%+ access; $400M Brazil pertuzumab contract begins Q4 FY2027, U.S. launch set for Q3 2028.
  • Shares rose 0.19% to $343.65 in muted reaction; stock trades 23% below 52-week high despite 'excellent' financial health score from InvestingPro.
  • CEO Tambe emphasized focus on margins, free cash flow, and debt reduction; interest costs fell 12% year-over-year as deleveraging continues.
Last Updated: 04/11/2026, 11:42
Read Full Transcript

Earnings

Latest Release
04/11/2026
EPS / Forecast
0.30 / 0.97
Revenue / Forecast
43.89B / 45.93B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.94
Dividend Yield
0.14%
Industry Median 0.17%
Annualised payout
0.50
Paid annually
5-Years Growth
-
Growth Streak

Biocon (BIOCON) Income Statement & Profits

Compare BIOCON to Peers and Sector

Metrics to compare
BIOCON
Peers
Sector
Relationship
P/E Ratio
132.7x35.6x−0.2x
PEG Ratio
−5.370.040.00
Price/Book
1.7x3.9x2.6x
Price / LTM Sales
3.4x4.3x2.8x
Upside (Analyst Target)
12.3%7.3%60.9%
Fair Value Upside
Unlock−6.4%9.5%Unlock

Biocon Limited, together with its subsidiaries, manufactures biotechnology products and offers research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics; Biosimilars; and Contract Research, Development and Manufacturing Organization (CRDMO) segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, central nervous system, anti-cancer/oncology, multiple sclerosis, immunosuppressants, and specialty molecules; and biosimilars products for oncology, diabetes, and immunology therapeutic areas. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal health, consumer goods, and specialty chemical industries, as well as academic institutions, non-profit organizations, and government agencies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

Employees
16447
Market
India

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
495.38M30.42%182.55B
Other Institutional Investors
31.58M1.94%11.64B
Public Companies & Retail Investors
1.10B67.64%405.84B
Total
1.63B100.00%600.03B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
SBI Funds Management Limited8.17%132,991,28549,007,289
Life Insurance Corporation of India3.83%62,335,70422,970,707

People Also Watch

1,215.90
ZYDU
+1.37%
2,454.00
LAUL
+3.54%
8,549.50
APLH
+1.42%
4,505.90
TVSM
+0.59%
1,855.30
ARBN
+2.84%

FAQ

What Is the Biocon (NSE: BIOCON) Share Price Today?

The Biocon stock price today is 368.50 INR.

What Stock Exchange Does Biocon (BIOCON) Trade On?

Biocon is listed and trades on the India National Stock Exchange.

What Is the Ticker (Stock Symbol) for Biocon?

The stock symbol (also called a 'ticker') for Biocon is "BIOCON."

Does Biocon Pay Dividends? What’s The Current BIOCON Dividend Yield?

Yes, BIOCON Pays Dividends to its Shareholders. The current Biocon dividend yield is 0.1%%.

What Is the Current Biocon Market Capitalisation?

As of today, Biocon (NSE: BIOCON) market cap is 600.03B INR.

What Is Biocon's (BIOCON) Earnings Per Share (TTM)?

The Biocon EPS is currently 2.94 (Trailing Twelve Months).

When Is the Next Biocon Earnings Date?

Biocon's next earnings report will be released on 04/02/2027.

Is BIOCON a Buy or Sell From a Technical Analyst Perspective?

Based on today's Biocon moving averages and other technical indicators, the daily buy/sell signal for BIOCON stock is Strong Buy.

How Many Times Has Biocon Stock Split?

Biocon has split 3 times. (See the BIOCON stock split history page for full effective split date and price information.)

How Many Employees Does Biocon Have?

Biocon has 16447 employees, based on their latest Companies House report.

What is the current trading status of Biocon (NSE: BIOCON)?

As of 11/11/2026, Biocon (BIOCON) is trading at a share price of 368.50 INR, with a previous close of 368.50 INR. The stock has fluctuated within a day range of 365.00 INR to 375.45 INR, while its 52-week range spans from 318.40 INR to 447.15 INR.

What Is Biocon (BIOCON) Price Target According to Analysts?

The average 12-month price target for Biocon is 415.00 INR, with a high estimate of 490 INR and a low estimate of 326 INR. 12 analysts recommend buying the stock, while 4 suggest selling, leading to an overall rating of Buy. The stock has an +12.62% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.